oops - Lilly’s Alzheimer’s Disease Drug Fails in
oops -
Lilly’s Alzheimer’s Disease Drug Fails in Final-Stage Trial
November 23, 2016 — 6:52 AM EST
NYSE $75.99
Solanezumab didn’t do better than placebo on cognitive tests
Drugmakers shares drop 14 percent, Biogen also falls
Eli Lilly & Co.’s experimental Alzheimer’s treatment solanezumab failed to slow the progression of the neurodegenerative disease, yet another setback to drugmakers and researchers who continue to seek a way to treat one of the most feared ailments in the world.
Patients treated with the drug didn’t show a meaningful slowing of cognitive decline compared to those who got a placebo, Lilly said in a statement Wednesday. The drugmaker said it hasn’t decided what next steps, if any, to take with the drug.
The results of the trial “were not what we had hoped for and we are disappointed for the millions of people waiting for a potential disease-modifying treatment,” said John Lechleiter, Lilly’s outgoing CEO. “We will evaluate the impact of these results on the development plans for solanezumab and our other Alzheimer’s pipeline assets.”
The findings are the latest setback in the quest to find a treatment for Alzheimer’s disease, which affects more than 5 million Americans and 40 million people worldwide. More than 100 compounds have failed to show they could slow the condition that robs patients of their minds and eventually their ability to care for themselves.
The shares fell 14 percent to $65.15 at 6:59 a.m. in New York, before the markets opened. Shares of Biogen Inc., which is developing an Alzheimer’s treatment considered closest behind Lilly’s, fell 6 percent to $299.
Trial Failure
Lilly will take a $150 million pretax charge, or about 9 cents a share after tax, related to the trial. It plans to announce 2017 guidance on Dec. 15.
Results from the large, final-stage clinical trial showed that patients with mild Alzheimer’s who took solanezumab didn’t respond better than patients given a placebo on tests of memory and mental function, the Indianapolis-based company said. The drug is designed to latch onto and isolate soluble forms of beta amyloid, the protein that experts believe turns toxic when it forms into clumps between the brain’s synapses.
Lilly said that other measures in the trial “directionally favored” the drug compared to placebo, but the differences were small. More data from the trial will be presented next month at a medical meeting.
Featured stocks: Coffee Shoppe
For conservative debate: "Keeping it Real"
Game Changing stock $SHMP
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Medicare Advantage's audit bill just landed with a nasty thud. UnitedHealth Group shares fell more than 10% on November 18 after the Centers for Medicare & Medicaid Services proposed new anti-fraud, audit, and repayment rules for the program. For holders of NYSE:UNH, this was not some sleepy policy memo buried in a federal filing cabinet. It was a hard reminder that...
Continue Reading
Five million patient histories are not a flashy product demo. They are a serious raw-material advantage, provided the data can be protected, organized, and made useful without turning clinical research into a carnival of loose claims. That is the real weight behind nference's long-term collaboration with Cedars-Sinai, announced November 20, 2026. The pair plan to build a...
Continue Reading
A retail-property security mandate rarely makes anyone pound the table, and frankly it should not. Still, YYForce has landed a tangible two-year contract in Singapore worth roughly S$831,120, with subsidiary Uniforce Security Services set to begin work on December 1, 2026. For NASDAQ:YFOR investors, this is the kind of small, operationally real win that deserves a sober...
Continue Reading
Six pages were never going to carry the weight of a complicated enterprise pitch. PinnacleQM has rebuilt its public face from a basic brochure into a library of more than 50 pages, putting its quality engineering, testing, automation and AI assurance work in clearer view for Australian technology and business buyers. This is not the sort of announcement that changes a...
Continue Reading
Agency technology hires usually land with all the thunder of a stapler dropping, but this one deserves a closer look. Mindgruve has named Steve Terjeson vice president of technology, handing a former WPP Choreograph executive the job of leading its software development and data engineering teams. The assignment is not vague: push AI innovation, make the proprietary...
Continue Reading
A dinosaur race may sound like pure kid bait, but the underlying idea is sturdier than that. Cardiac Solutions and the Seale family are backing an interactive health-and-performance exhibit at Tuscaloosa’s planned Saban Center, a project intended to turn questions about movement, fitness, heart rate and oxygen levels into something children can actually touch, test and...
Continue Reading
Landfill gas is messy stuff, which is exactly why Hydron Energy’s Bailey Landfill demonstration in Chilliwack deserves more attention than another clean-energy press release. The British Columbia company is putting its INTRUPTor™ gas-separation system into an operating environment alongside FortisBC and the City of Chilliwack, where the machinery has to deal with real...
Continue Reading
A Quiet Vendor Failure Can Become a Loud Problem Tax files are not ordinary customer records, and that is why this reported Baker Tilly Advisory Group breach deserves more than the usual shrug people give cyber incidents. Names and addresses are bad enough; the potential exposure of Social Security numbers and other sensitive information turns a systems failure into a...
Continue Reading
Twenty-one years is a long time to keep a corporate promise from turning into wallpaper. L’Oréal Paris gathered its 2026 Women of Worth class at the Ebell in Los Angeles on November 18, recognizing 10 nonprofit leaders working on problems that do not yield to a glitzy evening or a tidy slogan. That distinction matters. Cancer survivorship, trafficking prevention,...
Continue Reading
A swan latte taking 18 seconds less is not nothing, even if it is hardly a verdict on the future of coffee. COFE+, the seventh-generation robotic barista from Shanghai Hi-Dolphin Robot Technology, beat an award-winning human barista across five drinks at a live November 14 competition in Yiwu. That is a clean, visible demonstration of what machines are increasingly built...
Continue Reading
Top 5 Most Recently Viewed Articles
Exciting Advances in Nuclear Electric Propulsion Space Nuclear Power Corporation has embarked on a groundbreaking partnership with the United States Space Force (USSF) and the Space Strategic Technology Institute hosted by a prominent Michigan university. This collaboration aims to develop advanced nuclear electric propulsion systems designed for future space missions....
Continue Reading
Dali's Ecological Achievements Take Center Stage Dali, a picturesque city in Yunnan, China, has become a beacon of ecological progress, recently showcasing its achievements at the 2024 Erhai Forum on Global Ecological Civilization Construction. With a theme centered on 'Working Together to Promote Eco-Friendly Modernization', this important event took place in October and...
Continue Reading
Update for Investors of Wolfspeed, Inc. Wolfspeed, Inc. (NYSE: WOLF) has become the center of attention as investors seek justice after experiencing significant losses. Those who have purchased securities between specific dates are being invited to take action regarding a potential case of securities fraud. Understanding the Class Action Opportunity The Rosen Law Firm, a...
Continue Reading
Overview of Schouw & Co. Share Buy-Back Programme On May 5, Schouw & Co. took a significant step in enhancing shareholder value by launching a share buy-back programme. As outlined in their company announcement from May 2, the initiative allows for the acquisition of shares valued up to DKK 120 million. The duration of this programme extends from May 5 to December 31....
Continue Reading
Academy Sports and Outdoors Expands Its Reach Academy Sports and Outdoors, Inc. (NASDAQ: ASO) is executing an ambitious plan to bolster its presence through multi-state expansion. This entails the opening of new store locations while nurturing community partnerships aimed at enhancing value for shoppers. Recent Store Openings Recently, the retailer has launched new...
Continue Reading